Eye health formula from Sabinsa support symptoms of macular degeneration, says recent study


A recently-published study found that a branded eye health formula from Sabinsa Corp. called Macumax supported symptoms of age-related macular degeneration.

macular degeneration

Photo © iStockphoto.com/fotoadrenalina

A study recently published in the Journal of Medicinal Food1, found that a branded eye health formula from Sabinsa Corp. (East Windsor, NJ) called Macumax supported symptoms of age-related macular degeneration (AMD). Macumax contains xanthophyll carotenoids Lutein and Zeaxanthin with bioavailability enhancer BioPerine supplemented with Bilberry and Saffron extracts along with Zinc monomethionine.

In the study, 40 patients over the ages of 50 with early-stage dry-type AMD received one capsule of Macumax twice daily for 90 days. Subjects were assessed at baseline and thirty-day intervals through physical examination, vital signs, and assessment of subjective and objective symptoms. Results showed that overall, patients showed improvements in subject symptoms such as vision scores after treatment, compared to baseline. Changes in diminished and distorted vision scores were found to be significant at day 60. When it came to objective symptoms, researchers found that 40% of subjects had abnormal Amsler's grid aberration scores on day 90 compared with 77.5% of subjects at the beginning of the study.

“The maintenance of AMD symptoms from further deterioration is of paramount importance,” said Sabinsa founder and chairman Muhammed Majeed, PhD, in a press release. “Nutritional supplementation seems to hold great promise in that area. We are happy with the trial outcome, and look forward to continuing investigations.”


  1. Majeed M et al. “An open-label pilot study on Macumax supplementation for dry-type age-related macular degeneration.” Journal of Medicinal Food, Published online ahead of print on August 27, 2020
Related Videos
woman working on laptop computer by window
Related Content
© 2024 MJH Life Sciences

All rights reserved.